Sign up to our newsletter
and receive exclusive information and discount coupons straight to your inbox

Top news by writer

Daniel Tomas
Tehnology Writer

HEALTH / The daily deal : a neck massager at an unbeatable price
As of this week, helpmeoutDOC has begun offering a series of massively discounted health items for sale. Today it is time to introduce our readers…
July 28, 2016 | 0 comments

Gabriel Rosoga
Medical and Health Writer

BEAUTY & SKIN CARE / Bee venom serums work miracles on skin
Bee venom, when used in small dosis, proves to be a very effective natural medicine, with extremely beneficial impact on the human organism, with particular…
September 8, 2016 | 1 comment

Ion Gireada
Science Writer

HEALTH / Reasons why your brain hears a ringing
Brain activity in people affected by tinnitus is very different from what happens when sound is detected in brains of healthy people, new research uncovered.…
April 27, 2015 | 0 comments

Ionut Popescu
Health and lifestyle writer

HEALTH / Brits oblivious to obesity leading to cancer
British population largely unware of link between obesity and cancer, finds new survey conducted by the organization Cancer Research UK. According to the survey, 75%…
September 9, 2016 | 0 comments

New drug delays progression of thyroid cancer

by Ion Gireada on 13 February 2015
Health, Medical technology     |      lenvatinib,  radioactive iodine,  thyroid cancer

A new thyroid cancer drug may delay the progression of the disease five times longer, new research shows.

The new oral drug called lenvatinib acts as a targeted therapy that fights cancer by preventing the growth of new blood vessels that feed the cancer, researchers explained.

In clinical trials, lenvatinib slowed down the progression of advanced thyroid cancer by 18 months, compared with four months in patients that received a placebo.

“It’s an encouraging time for the advancement of treating patients with many different kinds of cancer,” said Dr. Gregory Masters, of the new targeted therapies. Masters is an oncologist at Christiana Care Health System in Newark, Del., and a member of the American Society of Clinical Oncology.

The findings of the research were published in New England Journal of Medicine.

The only treatment available to people with advanced thyroid cancer has been radioactive iodine, said study leader Dr. Steven Sherman, associate to vice provost for clinical research, and professor and chair of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in Houston.

But more than half of patients do not respond to radioactive iodine treatment, Sherman said. Moreover, thyroid cancers have a tendency to become resistance to radioactive iodine over time, making the therapy less and less effective.

“It’s been a disease where it’s been very difficult to treat once it’s become resistant to radioactive iodine,” Masters said.

Lenvatinib must await U.S. Food and Drug Administration approval for use against thyroid cancer, Masters said.

New drug delays progression of thyroid cancer

facebook pinterest google+